ArticlePharmacoEconomics2004

Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.

Peter K Schädlich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.